.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

LIPID PROFILE, BASIC, SERUM

(Spectrophotometry, Calculated)
Cholesterol Total 147.00 mg/dL <170.00
Triglycerides 102.00 mg/dL <150.00
HDL Cholesterol 48.20 mg/dL 40.00 - 60.00
LDL Cholesterol,Direct 88.00 mg/dL <110.00
VLDL Cholesterol 10.80 mg/dL <30.00
Non-HDL Cholesterol 98.80 mg/dL
Interpretation
--------------------------------------------------------------------
| NCEP | TOTAL | TRIGLYCERIDE | LDL CHOLESTEROL |
| RECOMMENDATIONS | CHOLESTEROL | in mg/dL | in mg/dL |
| | in mg/dL | | |
|-------------------|---------------|--------------|-----------------|
| Optimal | <170 | <150 | <110 |
|-------------------|---------------|--------------|-----------------|
| Borderline High | 171-199 | 150-199 | 111-129 |
|-------------------|---------------|--------------|-----------------|
| High | >=200 | 200-499 | >=130 |
|-------------------|---------------|--------------|-----------------|
| Very High | - | >=500 | - |
--------------------------------------------------------------------
Note
1. Measurements in the same patient can show physiological & analytical variations. Three serial samples
1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
2. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status.
Selective screening of children above the age of 2 years with a family history of premature
cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
3. NCEP identifies elevated Triglycerides as an independent risk factor for Coronary Heart Disease (CHD).
4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to
participate in reverse cholesterol transport, the process by which cholesterol is eliminated from
peripheral tissues.
5. ATP III guidelines uses LDL Cholesterol as the primary target for cholesterol lowering therapy. Note that
major risk factors can modify LDL goals.

NON HDL CHOLESTEROL

-----------------------------------------------------------------------
| RISK CATEGORY | LDL GOAL ( mg/dL) | NON HDL GOAL ( mg/dL)|
|----------------------|-------------------------|----------------------|
| CHD & CHD risk | < 100 | < 130 |
| equivalent (10 year | | |
| risk for CHD > 20 %) | | |
-----------------------------------------------------------------------

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*140345583* Page 1 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

-----------------------------------------------------------------------|
| Multiple (2+) Risk | < 130 | < 160 |
| Factors and 10 year | | |
| risk < or = 20% | | |
|----------------------|-------------------------|----------------------|
| 0-1 Risk factor | < 160 | <190 |
-----------------------------------------------------------------------

Comment:
ATP III suggested the addition of Non HDL Cholesterol (Total Cholesterol - HDL Cholesterol) as an indicator of
all atherogenic lipoproteins ( Mainly LDL & VLDL). The Non HDL Cholesterol is used as a secondary target of
therapy in persons with triglycerides >=200 mg/dL. The goal for Non HDL Cholesterol in those with increased
triglyceride is 30 mg/dL above that set for LDL Cholesterol.
For calculation of CHD risk, history of smoking, any medication for hypertension & current blood pressure
levels are required.

LIVER & KIDNEY PANEL, SERUM

(Spectrophotometry, Indirect ISE)
Bilirubin Total 0.37 mg/dL 0.30 - 1.20
Bilirubin Direct 0.10 mg/dL <0.20
Bilirubin Indirect 0.27 mg/dL <1.10
AST (SGOT) 35 U/L <50
ALT (SGPT) 14 U/L <50
GGTP 10 U/L 3.00 - 22.00
Alkaline Phosphatase (ALP) 171 U/L 93 - 309
Total Protein 7.10 g/dL 6.00 - 8.00
Albumin 4.47 g/dL 3.80 - 5.40
A : G Ratio 1.70 0.90 - 2.00
Urea 29.00 mg/dL 10.00 - 38.00
Creatinine 0.27 mg/dL 0.30 - 0.70
Uric Acid 3.80 mg/dL 3.50 - 7.20
Calcium, Total 9.70 mg/dL 8.80 - 10.80
Phosphorus 3.50 mg/dL 3.20 - 5.80
Sodium 135.00 mEq/L 138.00 - 145.00
Potassium 4.46 mEq/L 3.40 - 4.70
Chloride 104.00 mEq/L 101.00 - 109.00

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*140345583* Page 2 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*140345583* Page 3 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

COMPLETE BLOOD COUNT (CBC)

(Electrical Impedance & VCS,Photometry )

Hemoglobin 11.70 g/dL 11.00 - 14.00

Packed Cell Volume (PCV) 35.00 % 34.00 - 40.00
RBC Count 3.68 mill/mm3 4.00 - 5.20
MCV 95.10 fL 75.00 - 87.00
MCH 31.90 pg 24.00 - 30.00
MCHC 33.60 g/dL 31.00 - 37.00
Red Cell Distribution Width (RDW) 12.90 % 11.50 - 14.50
Total Leukocyte Count (TLC) 9.90 thou/mm3 5.00 - 15.00
Differential Leucocyte Count (DLC)

Segmented Neutrophils 38.40 %

Lymphocytes 49.20 %

Monocytes 8.00 %

Eosinophils 3.60 %

Basophils 0.80 %
Absolute Leucocyte Count

Neutrophils 3.80 thou/mm3 1.50 - 8.00

Lymphocytes 4.87 thou/mm3 6.00 - 9.00
Monocytes 0.79 thou/mm3 0.20 - 1.00
Eosinophils 0.36 thou/mm3 0.10 - 1.00
Basophils 0.08 thou/mm3 0.01 - 0.10
Platelet Count 307.0 thou/mm3 150.00 - 490.00
Note
1. As per the recommendation of International council for Standardization in Hematology, the differential
leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of
blood

2. Test conducted on EDTA whole blood

*140345583* Page 4 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

Physical

Chemical

URINE EXAMINATION, ROUTINE; URINE, R/E Sample Not Received

SNR01-

Microscopy

PatientReportSCSuperPanel.URINE_EXAMINATION_SC (Version: 6)

*140345583* Page 5 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD 7.3 %

(HPLC, NGSP certified)

Interpretation
-------------------------------------------------------------------------------
| As per American Diabetes Association (ADA) |
|-------------------------------------------------------------------------------|
| Reference Group | HbA1c in % |
|-------------------------------|-----------------------------------------------|
| Non diabetic adults >=18 years| <5.7 |
|-------------------------------|-----------------------------------------------|
| At risk (Prediabetes) | 5.7 - 6.4 |
|-------------------------------|-----------------------------------------------|
| Diagnosing Diabetes | >= 6.5 |
|-------------------------------|-----------------------------------------------|
| Therapeutic goals for glycemic| Age > 19 years |
| control | . Goal of therapy: < 7.0 |
| | . Action suggested: > 8.0 |
| | |
| | Age < 19 years |
| | . Goal of therapy: <7.5 |
-------------------------------------------------------------------------------

Note: 1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a
diabetic patient who is recently under good control may still have a high concentration of
HbA1c. Converse is true for a diabetic previously under good control but now poorly
controlled .
2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long
life expectancy and no significant cardiovascular disease. In patients with significant
complications of diabetes, limited life expectancy or extensive co-morbid conditions,
targeting a goal of < 7.0 % may not be appropriate.

Comments
HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better
indicator of long term glycemic control as compared to blood and urinary glucose determinations.

ADA criteria for correlation between HbA1c & Mean plasma glucose levels
---------------------------------------
| HbA1c(%) | Mean Plasma Glucose (mg/dL)|
|----------|----------------------------|
| 6 | 126 |
|----------|----------------------------|
| 7 | 154 |
|----------|----------------------------|
| 8 | 183 |
|----------|----------------------------|

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*140345583* Page 6 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

| 9 | 212 |
|----------|----------------------------|
| 10 | 240 |
|----------|----------------------------|
| 11 | 269 |
|----------|----------------------------|
| 12 | 298 |
---------------------------------------

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*140345583* Page 7 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

INSULIN, RANDOM, SERUM 5.70 µU/mL Not Established
(CMIA)
Note
1. A single random blood sample for insulin may provide insufficient information due to wide variation in the
time responses of insulin levels and blood glucose.
2. Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino
acids, growth hormone and catecholamines.
3. Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with
bovine or porcine insulin.

Clinical Utility
· Evaluation of fasting hypoglycemia
· Evaluation of Polycystic Ovary syndrome
· Classification of Diabetes mellitus
· Predict Diabetes mellitus
· Assessment of Beta cell activity
· Select optimal therapy for Diabetes
· Investigation of insulin resistance
· Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism,
Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism

Decreased levels - Untreated Type I Diabetes mellitus

TISSUE TRANSGLUTAMINASE (tTG) ANTIBODY, 5.53 Units <20.00

IgA, SERUM
(EIA)
Interpretation
-----------------------------------------------------------------
| RESULT IN Units | REMARKS |
|---------------------------|-------------------------------------|
| < 20 | Negative |
|---------------------------|-------------------------------------|
| 20 - 30 | Weak Positive |
|---------------------------|-------------------------------------|
| > 30 | Positive |
-----------------------------------------------------------------

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*140345583* Page 8 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

Note
1. To diagnose Celiac disease the test should be performed before eliminating gluten from the diet.
2. False positive results are seen in Type 1 Diabetes, Chronic Liver Disease, Heart Failure and
Psoriatic or Rheumatoid Arthritis. It is likely that proteins other than tTG may act as antigens for
anti-tTG antibodies.
3. False negative results may be seen in children below 2 years & patients with IgA deficiency.
There Is high prevalence of IgA deficiency in Celiac disease thus simultaneous screening for IgA
level has been recommended.

Comments
This test is used for the determination of IgA autoantibodies to human tissue transglutaminase for the
differential diagnosis of Celiac disease / Gluten sensitive enteropathy (GSE). Celiac disease is characterized
by small intestinal damages with flat mucosa leading to malabsorption with depletion of key nutrients. Tissue
transglutaminase is one of the main endomysial autoantigens that can be easily detected for the diagnosis of
Celiac disease. Other recommended tests are Endomysial, Gliadin & Reticulin antibodies along with small
intestinal biopsy. Negative serology does not exclude a diagnosis of GSE. IgA deficiency should be
considered in patients with suggestive clinical presentation.

VITAMIN D, 25 - HYDROXY, SERUM 14.36 nmol/L 75.00 - 250.00

(CLIA)
Interpretation
-------------------------------------------------------------
| LEVEL | REFERENCE RANGE | COMMENTS |
| | IN nmol/L | |
|---------------|-----------------|---------------------------|
| Deficient | < 50 | High risk for developing |
| | | bone disease |
|---------------|-----------------|---------------------------|
| Insufficient | 50-74 | Vitamin D concentration |
| | | which normalizes |
| | | Parathyroid hormone |
| | | concentration |
|---------------|-----------------|---------------------------|
| Sufficient | 75-250 | Optimal concentration |
| | | for maximal health benefit|
|---------------|-----------------|---------------------------|
| Potential | >250 | High risk for toxic |
| intoxication | | effects |
-------------------------------------------------------------

Note
PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*140345583* Page 9 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

· The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
· 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
· Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
· It shows seasonal variation, with values being 40-50% lower in winter than in summer.
· Levels vary with age and are increased in pregnancy.
· A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available

Comments
Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency
in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and
Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major
circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

Decreased Levels
· Inadequate exposure to sunlight
· Dietary deficiency
· Vitamin D malabsorption
· Severe Hepatocellular disease
· Drugs like Anticonvulsants
· Nephrotic syndrome

Increased levels
Vitamin D intoxication

ENDOMYSIAL ANTIBODY, IgA

(IFA)

Endomysial Antibody Negative

Titer 1:10

Note
1. Autoimmune reactivities are not by themselves diagnostic, but must be correlated with other laboratory
& clinical findings
2. A useful test for exclusion of Celiac disease is HLA - DNA testing for the presence of DQ 2 (DQB1*02,

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*140345583* Page 10 of 11
.

S16 - PSC FARIDABAD SECTOR-35

H.NO-180, ASHOK ENCLAVE MAIN, SEC-35, FA
RIDABAD, HARYANA - 121003
FARIDABAD

Name : Master AARAV SINGH Collected : 9/3/2018 9:33:00AM

Received : 9/3/2018 9:53:35AM
Lab No. : 140345583 Age: 4 Years Gender: Male Reported : 11/3/2018 11:47:47AM
A/c Status : P Ref By : Dr. SANDEEP Report Status : Final

Test Name Results Units Bio. Ref. Interval

DQA1*05) and DQ8 (DQB1*03, DQA1*03). Celiac disease can be excluded in 90% cases if all these
alleles are negative
3. Test conducted on Serum

Comments
IgA class of Endomysial antibodies are present in nearly 100% patients of Celiac disease. Thus their
identification is considered diagnostically sensitive and specific for Gluten sensitive enteropathies. Positivity is
also seen in some cases of Dermatitis herpetiformis.
---------------------------------------------------------
| DISEASE | PERCENT POSITIVITY |
|--------------------------------|------------------------|
| Confirmed Celiac disease | |
| On Gluten | 100 |
| On Gluten free diet | 46 |
|--------------------------------|------------------------|
| Suspected Celiac disease | |
| On Gluten | 90 |
| On Gluten free diet | 17 |
|--------------------------------|------------------------|
| Dermatitis herpetiformis | 80 |
---------------------------------------------------------

Dr. Ritu Nayar Dr. Shalabh Malik Dr. Anil Arora Dr Biswadip Hazarika
MD (Microbiology) MD (Microbiology) MD (Pathology) MD (Pathology)
Deputy HOD Microbiology & Serology - National Head - Microbiology & HOD Hemat & Imm - NRL Sr. Consultant Pathologist - NRL
NRL Serology - NRL

Dr Himangshu Mazumdar Dr. Nimmi Kansal

MD (Biochemistry) MD (Biochemistry)
Consultant Biochemist - NRL HOD Biochem & IA - NRL

-------------------------------End of report --------------------------------

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*140345583* Page 11 of 11